Deals channel feed

When is a pre­clin­i­cal drug worth a moth­er lode of cash? This top 20 list of­fers a few an­swers

3 years ago
Bioregnum
R&D

Re­cur­sion ac­quires two AI-based drug dis­cov­ery com­pa­nies in $87.5M deal

3 years ago

Gink­go and Boehringer In­gel­heim sign pact to mine mi­crobes and find new mol­e­cules

3 years ago
Pharma

San­doz joins up with B2B phar­ma to com­mer­cial­ize six biosim­i­lars in the US

3 years ago
Pharma

Alessan­dro Ri­va takes over Trans­gene as As­traZeneca walks away from on­colyt­ic virus pact

3 years ago
People

On heels of Es­sex deal, CRO Emmes says it's plan­ning to make more ac­qui­si­tions this year

3 years ago
Outsourcing
Manufacturing

Re­verse merg­ers say hey as biotechs trade low, hunt for al­ter­na­tives and launch few IPOs

3 years ago
Financing
Startups

Forge Bi­o­log­ics se­cures man­u­fac­tur­ing and de­vel­op­ment deal with Lab­Corp

3 years ago
Pharma
Manufacturing

As­traZeneca en­ters pre­clin­i­cal cell ther­a­py deal with Cana­di­an biotech

3 years ago
Cell/Gene Tx

Ma­gen­ta sets up Di­anthus merg­er in quick, three-month about-face af­ter end­ing tri­al due to pa­tient death

3 years ago
Startups

J&J goes block­buster hunt­ing (again) with $245M cash up­front for next-gen CAR-T

3 years ago
Bioregnum

Prometheus re­port­ed­ly drew a com­pet­ing Ab­b­Vie bid, ini­tial part­ner in­ter­est from 16 phar­mas be­fore ink­ing $10.8B Mer­ck buy­out

3 years ago
Pharma

ROCK2 Part 2: Sam Wak­sal’s Gravi­ton pairs up with Ovid Ther­a­peu­tics in rare CNS in­di­ca­tions

3 years ago
Startups

Sanofi's next chap­ter in Pompe: $150M for Maze pact as the biotech gears up in CKD

3 years ago
Startups
Pharma

Astel­las to buy Iver­ic Bio for $5.9B in cash as biotech awaits Au­gust FDA nod in reti­nal dis­ease

3 years ago
Pharma

Com­pa­ny found­ed by ex-No­var­tis ex­ecs inks $477M in-li­cense deal

3 years ago

Quest Di­ag­nos­tics buys Bert Vo­gel­stein’s Haystack On­col­o­gy, just six months af­ter Se­ries A

3 years ago
Diagnostics

One SPAC inks biotech merg­er, while an­oth­er linked to for­mer Biden can­cer moon­shot leader will shut down

3 years ago
Financing

MD An­der­son, Flag­ship start­up part­ner to de­sign and test can­cer drugs made with gen­er­a­tive AI

3 years ago
AI

As show­down with ac­tivist nears, Il­lu­mi­na’s CEO de­fends the com­pa­ny’s $7.1B pur­chase of Grail

3 years ago
Diagnostics

Serum In­sti­tute sub­sidiary in­vests an­oth­er $150M in­to Bio­con

3 years ago
Manufacturing

Enan­ta sells off over 50% of roy­al­ty pay­ments from Mavyret in ex­change for $200M

3 years ago
Pharma

No­var­tis pays Ger­man biotech $40M for ra­di­oli­gand ther­a­py, di­ag­nos­tic hit­ting 'first-in-class' tar­get

3 years ago

Flori­da-based biotech with ap­proved car­dio­vas­cu­lar ther­a­py moves to go pub­lic via SPAC

3 years ago
R&D
First page Previous page 35363738394041 Next page Last page
A service from the Financial Times